HOME >> BIOLOGY >> NEWS
UBC researcher discovers 'control room' that regulates immune responses

VANCOUVER, Canada -- The approximately 50 million people in the U.S. who suffer from autoimmune diseases like HIV/AIDS, multiple sclerosis, and arthritis, may soon be able to control their immune responses, thanks to a breakthrough discovery by a researcher at the University of British Columbia in Vancouver, Canada.

Wilfred Jefferies, a professor at UBC's Biotechnology Laboratory, has discovered and characterized the mechanics of a cellular pathway that triggers immune responses. He and his team have also uncovered a specialized cell substructure, or organelle, that dictates exactly how the immune system will be activated.

"This discovery opens the door to the immune system control room," says Jefferies, who is also a member of UBC's Biomedical Research Centre. "We've found a mechanism that appears to act like a dial it can turn immune system response up or down."

Jefferies believes that it will take about five years for scientists to use this information to create new therapies such as medication or vaccines to regulate immune responses in humans.

The findings have enormous implications for patients because treatment may be targeted by adjusting the "dial", says Jefferies. Immune responses may be increased to fight infection or reduced to help the body accept transplanted tissue or organs.

The work was recently published online in Nature Immunology and will be the topic of an editorial when the journal appears on newsstands in November.

The research findings can be used immediately to test exactly how the immune system responds to a variety of pathogenic organisms, including bacteria, viruses and tumours, says Jefferies, who is a member of UBC's departments of Microbiology and Immunology, Medical Genetics and Zoology.

Jefferies' research focuses on dendritic cells. A network of specialized cells, dendritic cells act as sentinels of the immune system, detecting and relaying information about illness-c
'"/>

Contact: Hilary Thomson
hilary.thomson@ubc.ca
604-822-2644
University of British Columbia
22-Oct-2003


Page: 1 2

Related biology news :

1. Belgian researchers explore revolutionary approach to angiogenesis
2. Award winning researchers reveal potential new role for Glivec
3. University of Alberta researcher looks for clues to mysterious disease
4. $7.5 Million grant to Yale researchers for role of viruses in cancer
5. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
6. Joslin researchers clarify mechanisms for beta-cell formation
7. Pioneering AIDS researcher to speak at UH
8. Defensive action by influenza viruses demonstrated by Hebrew university researcher
9. Virginia Tech researchers to release findings on Smith River Project
10. Molecular motor myosin VI moves hand over hand, researchers say
11. Tiny molecules have big potential as cancer drugs, Stanford researcher believes

Post Your Comments:
(Date:5/21/2013)... , May 21, 2013 Royal Philips Electronics ... the world,s first portable ultrasound with Philips, industry leading ... capability. The CX50 xMATRIX with available Live 3D TEE ... at the EuroPCR, official meeting for the ... Since its launch in 2012, Philips CX50 ...
(Date:5/21/2013)... modifications, which alter the way genes function without ... detected in the blood of pregnant women during ... foretell depression in the weeks after giving birth, ... debilitating. , The findings of the small study ... the journal Molecular Psychiatry . , "Postpartum ...
(Date:5/20/2013)... to the antibiotic colistin are also commonly resistant ... according to a study in mBio , ... for Microbiology. Cross-resistance to colistin and host antimicrobials ... against bacterial attack, could mean that patients with ... a crippled immune response. Colistin is a last-line ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
(Date:5/21/2013)... Toronto, Canada (PRWEB) May 21, 2013 ... there is a strong push within the industry ... Development and Manufacturing Organizations and pharma companies often ... time frames. , Microtablets, developed in collaboration with ... how effective outsourcing can bring products to market ...
(Date:5/21/2013)... May 21, 2013 Many have long ... contributor to acne. Recently physicians from Clinical Psychiatry.com ... stress on the skin, and suggested using hypnotherapy ... the chemicals produced from stress that cause acne. , ... negative feelings acne brings about, stress causes changes in ...
(Date:5/21/2013)... Emerson Resources Inc. , a premier pharmaceutical ... Company’s Chief Executive Officer and Chairman of the Board, ... service. As part of Emerson Resources’ planned leadership succession ... as Dr. Signorino’s successor. , Dr. Signorino is ... a significant contribution to the field during his extensive ...
(Date:5/21/2013)... 21, 2013  MacroGenics, Inc. today announced that ... (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in ... oncoprotein," will be presented at the 2013 Annual ... during the Developmental Therapeutics - Immunotherapy Oral Abstract ... 4:30 PM.  The presentation will describe the results ...
Breaking Biology Technology:The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: